行情

AFMD

AFMD

Affimed
NASDAQ

实时行情|Nasdaq Last Sale

1.560
-0.010
-0.64%
盘后: 1.560 0 0.00% 16:00 03/27 EDT
开盘
1.570
昨收
1.570
最高
1.735
最低
1.520
成交量
133.47万
成交额
--
52周最高
4.430
52周最低
1.420
市值
1.00亿
市盈率(TTM)
-8.4691
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测AFMD价格均价为7.27,最高价位10.39,最低价为5.20。

EPS

AFMD 新闻

更多
  • Affimed Announces Participation at Upcoming Virtual Investor Conferences
  • GlobeNewswire · 2天前
  • Solebury Trout Announces Virtual Conference Series with Presentations from Life Science Companies
  • ACCESSWIRE · 4天前
  • Affimed Announces Appointment of Arndt Schottelius, M.D. Ph.D. as Chief Scientific Officer
  • GlobeNewswire · 03/17 12:30
  • The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
  • Benzinga · 03/12 11:37

所属板块

生物技术和医学研究
-2.43%
制药与医学研究
-0.87%

热门股票

代码
价格
涨跌幅

AFMD 简况

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes FM13, AFM11, AFM21, AFM22, AFM24, TandAb and Trispecific Abs. It has started recruitment for Phase IIa clinical trial of AFM13 in patients with Hodgkin Lymphoma. It has initiated a Phase I clinical trial of AFM11 in patients with non-Hodgkin Lymphoma. AFM21 is in preclinical development. AFM22, which is an Epidermal Growth Factor Receptor variant III (EGFRvIII)/CD16A NK-cell TandAb is in preclinical development. AFM24 is an additional CD16A NK-cell TandAb targeting a validated solid tumor target, EGFR-wild type. It is developing Trispecific Abs for treating multiple myeloma, and CD33/CD3-specific T-cell TandAb to treat acute myeloid leukemia.
展开

微牛提供Affimed NV(NASDAQ-AFMD)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的AFMD股票新闻,以帮助您做出投资决策。